Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells - PubMed (original) (raw)
. 1997 Dec;27(12):3507-16.
doi: 10.1002/eji.1830271252.
D S Robinson, Q Meng, J Rottman, R Kennedy, D J Ringler, C R Mackay, B L Daugherty, M S Springer, S R Durham, T J Williams, A B Kay
Affiliations
- PMID: 9464841
- DOI: 10.1002/eji.1830271252
Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells
S Ying et al. Eur J Immunol. 1997 Dec.
Abstract
Eotaxin is a newly discovered C-C chemokine which preferentially attracts and activates eosinophil leukocytes by acting specifically on its receptor CCR3. The airway inflammation characteristic of asthma is believed to be, at least in part, the result of eosinophil-dependent tissue injury. This study was designed to determine whether there is increased expression of eotaxin and CCR3 in the bronchial mucosa of asthmatics and whether this is associated with disease severity. The major sources of eotaxin and CCR3 mRNA were determined by co-localization experiments. Bronchial mucosal biopsy samples were obtained from atopic asthmatics and normal non-atopic controls. Eotaxin and CCR3 mRNA were identified in tissue sections by in situ hybridization (ISH) using radiolabeled riboprobes and their protein product visualized by immunohistochemistry (IHC). Co-localization experiments were performed by double ISH/IHC. Eotaxin and CCR3 (mRNA and protein) were significantly elevated in atopic asthmatics compared with normal controls. In the asthmatics there was a highly significant inverse correlation between eotaxin mRNA+ cells and the histamine provocative concentration causing a 20% fall in FEV1 (PC20). Cytokeratin-positive epithelial cells and CD31+ endothelial cells were the major source of eotaxin mRNA whereas CCR3 co-localized predominantly to eosinophils. These data are consistent with the hypothesis that damage to the bronchial mucosa in asthma involves secretion of eotaxin by epithelial and endothelial cells resulting in eosinophil infiltration mediated via CCR3. Since selective (eotaxin) and non-selective C-C chemokines such as RANTES, MCP-3 and MCP-4 all stimulate eosinophils via CCR3, this receptor is potentially a prime therapeutic target in the spectrum of diseases involving eosinophil-mediated tissue damage.
Similar articles
- Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (Intrinsic) asthmatics.
Ying S, Meng Q, Zeibecoglou K, Robinson DS, Macfarlane A, Humbert M, Kay AB. Ying S, et al. J Immunol. 1999 Dec 1;163(11):6321-9. J Immunol. 1999. PMID: 10570327 - C-C chemokines in allergen-induced late-phase cutaneous responses in atopic subjects: association of eotaxin with early 6-hour eosinophils, and of eotaxin-2 and monocyte chemoattractant protein-4 with the later 24-hour tissue eosinophilia, and relationship to basophils and other C-C chemokines (monocyte chemoattractant protein-3 and RANTES).
Ying S, Robinson DS, Meng Q, Barata LT, McEuen AR, Buckley MG, Walls AF, Askenase PW, Kay AB. Ying S, et al. J Immunol. 1999 Oct 1;163(7):3976-84. J Immunol. 1999. PMID: 10491000 - Glucocorticosteroids inhibit mRNA expression for eotaxin, eotaxin-2, and monocyte-chemotactic protein-4 in human airway inflammation with eosinophilia.
Jahnsen FL, Haye R, Gran E, Brandtzaeg P, Johansen FE. Jahnsen FL, et al. J Immunol. 1999 Aug 1;163(3):1545-51. J Immunol. 1999. PMID: 10415058 Clinical Trial. - Eotaxin and asthma: some answers, more questions.
Corrigan CJ. Corrigan CJ. Clin Exp Immunol. 1999 Apr;116(1):1-3. doi: 10.1046/j.1365-2249.1999.00740.x. Clin Exp Immunol. 1999. PMID: 10209497 Free PMC article. Review. No abstract available. - CCR3 blockade as a new therapy for asthma.
Bertrand CP, Ponath PD. Bertrand CP, et al. Expert Opin Investig Drugs. 2000 Jan;9(1):43-52. doi: 10.1517/13543784.9.1.43. Expert Opin Investig Drugs. 2000. PMID: 11060659 Review.
Cited by
- Immunologic aspects of asthma: from molecular mechanisms to disease pathophysiology and clinical translation.
Xie C, Yang J, Gul A, Li Y, Zhang R, Yalikun M, Lv X, Lin Y, Luo Q, Gao H. Xie C, et al. Front Immunol. 2024 Oct 8;15:1478624. doi: 10.3389/fimmu.2024.1478624. eCollection 2024. Front Immunol. 2024. PMID: 39439788 Free PMC article. Review. - The cGAS-STING pathway in COPD: targeting its role and therapeutic potential.
Liao K, Wang F, Xia C, Xu Z, Zhong S, Bi W, Ruan J. Liao K, et al. Respir Res. 2024 Aug 7;25(1):302. doi: 10.1186/s12931-024-02915-x. Respir Res. 2024. PMID: 39113033 Free PMC article. Review. - CCL11 released by GSDMD-mediated macrophage pyroptosis regulates angiogenesis after hindlimb ischemia.
Wang Y, Gao Y, Shi H, Gao R, Yang J, Qu Y, Hu S, Zhang J, Wang J, Cao J, Zhang F, Ge J. Wang Y, et al. Cell Death Discov. 2024 Jun 21;10(1):294. doi: 10.1038/s41420-023-01764-9. Cell Death Discov. 2024. PMID: 38906863 Free PMC article. - Eotaxin-1/CCL11 promotes cellular senescence in human-derived fibroblasts through pro-oxidant and pro-inflammatory pathways.
Lavandoski P, Pierdoná V, Maurmann RM, Grun LK, Guma FTCR, Barbé-Tuana FM. Lavandoski P, et al. Front Immunol. 2023 Oct 4;14:1243537. doi: 10.3389/fimmu.2023.1243537. eCollection 2023. Front Immunol. 2023. PMID: 37860000 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous